The gut microbiome's role in hormone-dependent cancers goes deeper than previously thought. A new review proposes an "endocrine-microbiota axis" — a bidirectional relationship where gut bacteria influence hormone metabolism and hormones reshape microbial communities. This matters most for breast cancer, where nearly 80% of tumors are hormone-sensitive. The older concept of the estrobolome (bacteria that reactivate estrogens via specific enzymes) is now seen as just one piece of a much bigger picture.

Several mechanisms may link microbiome disruption to cancer development: gut dysbiosis can break down the intestinal barrier, triggering chronic low-grade inflammation; microbial metabolites may cause DNA damage or epigenetic changes; and local microbiota in breast and endometrial tissue may remodel the tumor microenvironment. Major hormonal life events — puberty, pregnancy, menopause — also appear to shift microbial composition in ways that could affect long-term cancer risk.

Key Takeaways:

• Gut bacteria can alter tamoxifen metabolism, potentially affecting its efficacy in breast cancer treatment
• Greater gut bacterial diversity is linked to better immunotherapy responses; low diversity worsens chemo-related GI toxicity
• Aromatase inhibitors may themselves reshape gut microbiota composition

Why it matters: Microbiome-targeted strategies — including probiotics, prebiotics, enzyme inhibitors, and fecal transplants — are under investigation, but evidence remains largely preclinical. Large-scale trials are needed to translate these findings into real clinical benefit.